Core Insights - SINTX Technologies has appointed Ryan Elmore as President, effective March 16, 2026, to accelerate revenue opportunities from its SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies [1][3]. Company Strategy - Mr. Elmore will lead the transition of SINTX from a product-focused medical device manufacturer to a broader biomaterials platform company, leveraging its proprietary silicon nitride expertise and expanding intellectual property portfolio [3][5]. - The company aims to commercialize silicon nitride technologies across various product categories, including sutures, mesh, and wound dressings, while expanding its capabilities to support multiple material forms [4][5]. Leadership Background - Ryan Elmore brings over 15 years of experience in advanced biomaterials and medical device commercialization, previously serving as Core Business Director at Invibio, a division of Victrex plc [2][5]. - His mandate includes implementing a disciplined commercial execution strategy to translate SINTX's platform assets into scalable revenue opportunities [5]. Product Development Focus - SINTX is focused on expanding the adoption of SiNERGY™ SiN/PEEK biocomposites and developing new product formats such as filament, rod, and sheet to support various manufacturing workflows [4][5]. - The company has established itself as a leader in high-performance biomaterials, with thousands of medical devices implanted since 2008 and a strong patent portfolio [8].